Adequate peri-implant and periodontal soft tissue volume and quality are increasingly recognized as key determinants of long-term treatment success. Tissue thickness, the width of keratinized tissue, and vascular supply all contribute to marginal bone preservation, resistance to inflammatory complications, predictable wound healing, and long-term esthetic outcomes around teeth and implants. While autogenous connective tissue grafts remain the clinical gold standard for soft tissue augmentation, their routine use is limited by donor-site morbidity, increased surgical time, limited tissue availability, and technique-sensitive harvesting procedures. These challenges become even more relevant when treating multiple sites or patients seeking minimally invasive treatment options.

Acellular dermal matrices have emerged as a proven alternative, enabling soft tissue augmentation without the need for a second surgical site. Native dermal matrix preserves the natural three-dimensional collagen architecture, providing a scaffold that supports rapid blood infiltration, early revascularization, cellular repopulation, and progressive remodeling into the patient’s own soft tissue. The result is predictable soft tissue integration with reduced patient morbidity and simplified clinical workflows.

Beyond the biological properties of the matrix itself, predictable clinical outcomes are supported by established surgical principles that promote uneventful healing and tissue integration. Careful graft adaptation, stable wound conditions, and appropriate flap management help create an optimal environment for revascularization and long-term tissue maturation.

In this webinar, participants will gain an evidence-based understanding of soft tissue augmentation with mucoderm®, from the biological principles of matrix integration to clinical indications, surgical handling, and practical techniques for achieving stable graft fixation, predictable healing, and long-term peri-implant and periodontal soft tissue stability.